The Parkinson's treatment has been shown to be a selective MAO-B inhibitor.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) yesterday reported that its Parkinson's disease treatment, Azilect (rasagiline), demonstrated selective MAO-B inhibition at the approved dose of one milligram. On the basis of the results of the positive results of this study, Teva will work with the US Food and Drug Administration (FDA) to modify the Azilect label to reflect this data.
Non selective MAO inhibitors may have some contra indications with certain foods and drugs. These limitations are not associated with selective MAO inhibitors and therefore they can be broadly prescribed.
In August, Teva published the full results of the Azilect trial, which showed that the drug slowed the progress of Parkinson's disease.
Teva rose 0.2% on Nasdaq yesterday to $42.95. The share fell 0.1% by midday on the TASE to NIS 160.90.
Published by Globes [online], Israel business news - www.globes-online.com - on November 4, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008